Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Cytoreductive Interventions in Metastatic Foregut Adenocarcinoma
NCT04931420Phase 2Withdrawn
- Sponsor
- University of Chicago
- Start
- May 2022
- Primary completion
- May 2026
01
Overview
Phase 2, randomised, open-label trial in esophageal adenocarcinoma (EAC), gastric adenocarcinoma, pancreatic adenocarcinoma (PDAC) and 4 more, sponsored by University of Chicago. Primary endpoint: Progression Free Survival at 12 months. Planned start May 2022; status: withdrawn.
02
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinomapancreatic adenocarcinoma (PDAC)cholangiocarcinoma (CCA)gallbladder adenocarcinoma
Beyond the preview
Go deeper on NCT04931420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931420.